MDXXFPharmAla Biotech Holdings Inc.

About PharmAla Biotech Holdings Inc. (MDXXF)

PharmAla Biotech Holdings Inc. (MDXXF) is a Biotechnology company headquartered in Toronto, ON, Canada whose shares trade over-the-counter on the OTCQB tier.

Pharmala is focused on manufacture of Active Pharmaceutical Ingredients, of the Substituted methylenedioxy- phenethylamines class ("MDXX"), including 3,4-Methylenedioxymethamphetamine ("MDMA"). Pharmala also intends to undertake development of novel formulations of MDMA and the MDXX class of compounds, as well as developing novel drug delivery pathways for these molecules.

Products and services

PharmAla is a manufacturer of Pharmaceutical products, as well as a researcher and developer of novel Central Nervous System (CNS) drugs for clinical use. It's current lead product is LaNeo MDMA, which is sold to clinical researchers globally and provided to patients in countries which allow for its use under their regulatory regimes.

MDXXF key facts

Ticker symbol

MDXXF

Market tier

OTCQB

Sector

Healthcare

Industry

Biotechnology

Headquarters

Toronto, ON, Canada

Country of incorporation

CA

Year of incorporation

2021

Employees

10

Estimated market cap

$11.24M (as of Apr 16, 2025)

Shares outstanding

105,182,708

Reporting standard

International Reporting: Canadian Securities Exchange

Audit status

Audited

Fiscal year end

8/31

Latest filing

Quarterly Report (Nov 30, 2024)

PharmAla Biotech Holdings Inc. leadership

• Nickolas Kadysh — President, CEO
• Shane Henry Morris — COO
• Will Avery — CFO
• Hugh Ferreira — Consultant
• Andrew Charles Newbury — Other
• Cesario Chan — Other

Explore more: Biotechnology stocks · Healthcare sector · OTCQB stocks · OTC stocks starting with M